Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Gut Microbiome in Acute Leukemia Post-Transplant
NCT06058572Phase 2Recruiting
- Sponsor
- Tata Memorial Centre
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifaximin in acute leukemia (2 arms), sponsored by Tata Memorial Centre. Primary endpoint: Impact of rifaximin on gut microbial diversity. Started Aug 2024; status: recruiting.
02
Drugs
rifaximin
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT06058572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058572.